BRISBANE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Nathan Standifer Ph.D., Executive Director of Translational Science at Tempest, will present a poster at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting taking place March 15-17, 2023 in Denver, CO and virtually. The poster highlights biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, showing an association between observed clinical benefit and fatty acid oxidation perturbations and gene expression.
| Poster presentation details: | |
| Title: | TPST-1120, a first-in-human peroxisome-proliferator activated receptor-alpha (PPAR-α) antagonist: scientific rationale, clinical activity and biomarker assessments |
| Date: | Thursday, March 16, 2023 |
| Time: | 6:00 - 7:30 p.m. MT |
| Abstract Number: | 78 |
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Aljanae Reynolds
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
____________________
1 If approved by the FDA
| Last Trade: | US$6.45 |
| Daily Change: | 0.32 5.20 |
| Daily Volume: | 17,099 |
| Market Cap: | US$281.430M |
May 13, 2025 April 21, 2025 March 27, 2025 March 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
